BUZZ - Arcus Biosciences shares plunge due to $250 million stock offering
路透社2026/10/22 09:41October 22 - ** Shares of biopharmaceutical company Arcus Biosciences (RCUS.N) fell 8.1% to $17.56 before the market opened on Thursday, nearing a one-year low, after the company priced a $250 million follow-on offering.
** RCUS, which focuses on cancer and immune diseases, sold about 14.3 million shares at $17.50 each on Wednesday evening (link), an 8.4% discount to the last closing price.
** Jefferies, Leerink, TD Cowen, Evercore, and Mizuho acted as joint bookrunners.
** According to the prospectus (link), the company plans to use the net proceeds for R&D, including expanding and accelerating the clinical development program for its drug casdatifan, as well as other general corporate purposes.
** RCUS, headquartered in Hayward, California, currently has about 127.3 million shares outstanding.
** RCUS shares plummeted 19.6% on Wednesday. The stock has declined by 36% over the past three months and is down about 20% year-to-date.
** According to LSEG data, 13 out of 15 analysts rate the stock as “strong buy” or “buy,” while 2 rate it as “hold”; the median target price is $43.50.
(To assist non-English speakers, Reuters offers automated translations of its reporting into several other languages. Because automated translation may contain errors or may not capture the intended context, Reuters does not guarantee the accuracy of the translated text and offers it solely for reader convenience. Reuters is not liable for any damage or losses resulting from the use of automated translation services.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin rebounds sharply from oversold levels, briefly surpassing $57,000

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix
According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.
"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."
Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.
Chun purchased 7,186 ETH worth $11.74 million
